<i>Listeria monocytogenes</i> Infection in Hairy Cell Leukemia: A Case Report and Literature Review

Barton, James C.; Edmunds, Hayward S.

doi:10.1155/2018/5616898

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic approach Because of disease-related neutropenia and monocytopenia, 62 as well as profound neutropenia and T-cell depletion secondary to therapy with PAs, 63 , 64 approximately 25% of patients with HCL experience a bacterial or opportunistic 65 , 66 , 67 , 68 infection at the onset or during the course of the disease.…”

Section: Diagnosis Of Refractory/relapsed Hclmentioning

confidence: 99%

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Falini

Carolis

Tiacci

2022

Blood

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) responds very well to frontline chemotherapy with purine analogs (cladribine and pentostatine). However, about half of patients experience one or more relapses, which become progressively resistant to these myelotoxic and immunosuppressive agents. At progression, standard therapeutic options include a second course of purine analogs alone or in combination with rituximab, and, upon second relapse, therapy with the anti-CD22 immunotoxin moxetumomab pasudotox. Furthermore, blockade of the mutant BRAF-V600E kinase (the pathogenetic hallmark of HCL) through orally available specific inhibitors (vemurafenib or dabrafenib) effaces the peculiar morphologic, phenotypic and molecular identity of this disease as well as its typical anti-apoptotic behaviour, and is emerging as an attractive chemotherapy-free strategy in various clinical scenarios. These include patients with, or at risk of, severe infections and, in a highly effective combination with rituximab, patients with relapsed or refractory HCL. Other treatments explored in clinical trials are BTK inhibition with ibrutinib and co-inhibition of BRAF (through dabrafenib or vemurafenib) and its downstream target MEK (through trametinib or cobimetinib). Here, we focus on our experience with BRAF inhibitors in clinical trials and as off-label use in routine practice by presenting three challenging clinical cases to illustrate their management in the context of all available treatment options.

show abstract

Section: Diagnosis Of Refractory/relapsed Hclmentioning

confidence: 99%

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Falini

Carolis

Tiacci

2022

Blood

View full text Add to dashboard Cite

show abstract

“…However, when an immunocompromised person is exposed to L.monocytogenes, the infection is inevitable. These include pregnant women, diabetic individuals, those with malignancy, individuals with acquired immunodeficiency syndrome, individuals taking steroids, or elderly individuals 8 . The patient in this case report was a seventy-four years old, immunocompromised cancer patient and had a likelihood of getting infected.…”

Section: Discussionmentioning

confidence: 99%

Listeria Monocytogenes, a Case of Mistaken Identity

Dogar,

Danish Iqbal,

Abdul Ahad

et al. 2022

Pak Postgrad Med J.

View full text Add to dashboard Cite

A 74 years old female patient who was a known case of Diabetes Mellitus, Hypertension, and Breast Cancer presented in the Accident and Emergency Department with complaints of fever, seizures, and an altered state of consciousness. The patient was febrile with a temperature of 40° C, blood pressure was 140/80 mmHg, and pulse was 90 beats/min. She was in an altered state of consciousness with a Glasgow Coma Scale score of 10/15. The rest of the physical examination was unremarkable. The pleomorphic nature of this bacterium and clinical presentation similar to meningitis caused by other micro-organisms make the laboratory and clinical diagnosis respectively rather difficult. We illustrate the clinical presentation, antibiotic therapy, and laboratory diagnosis of L.monocytogenes in a patient with weak immune status. A high clinical suspicion of Listeriosis is essential for prompt and accurate treatment if a case of meningitis is not responding to traditional empirical antibiotics, and especially in immunocompromised.

show abstract

“…Splenomegaly is common, while hepatomegaly and enlarged lymph nodes are rare. In about 20% of cases, opportunistic infections occur at diagnosis [ 12 ] and include mycobacterioses, Listeria monocytogenes infection, Toxoplasma gondii infection, cryptococcal meningitis or invasive fungal diseases [ 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ].…”

Section: Hairy-cell Leukemiamentioning

confidence: 99%

Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group

Paillassa,

Maitre,

Belarbi Boudjerra

et al. 2024

Cancers

View full text Add to dashboard Cite

Introduction: Hairy-cell leukemia (HCL) is a rare B-cell chronic lymphoproliferative disorder (B-CLPD), whose favorable prognosis has changed with the use of purine nucleoside analogs (PNAs), such as cladribine (CDA) or pentostatin (P). However, some patients eventually relapse and over time HCL becomes resistant to chemotherapy. Many discoveries have been made in the pathophysiology of HCL during the last decade, especially in genomics, with the identification of the BRAFV600E mutation and cellular biology, including the importance of signaling pathways as well as tumor microenvironment. All of these new developments led to targeted treatments, especially BRAF inhibitors (BRAFis), MEK inhibitors (MEKis), Bruton’s tyrosine kinase (BTK) inhibitors (BTKis) and recombinant anti-CD22 immunoconjugates. Results: The following major changes or additions were introduced in these updated guidelines: the clinical relevance of the changes in the classification of splenic B-cell lymphomas and leukemias; the increasingly important diagnostic role of BRAFV600E mutation; and the prognostic role of the immunoglobulin (IG) variable (V) heavy chain (H) (IGHV) mutational status and repertory. We also wish to insist on the specific involvement of bones, skin, brain and/or cerebrospinal fluid (CSF) of the disease at diagnosis or during the follow-up, the novel targeted drugs (BRAFi and MEKi) used for HCL treatment, and the increasing role of minimal residual disease (MRD) assessment. Conclusion: Here we present recommendations for the diagnosis of HCL, treatment in first line and in relapsed/refractory patients as well as for HCL-like disorders including HCL variant (HCL-V)/splenic B-cell lymphomas/leukemias with prominent nucleoli (SBLPN) and splenic diffuse red pulp lymphoma (SDRPL).

show abstract

Listeria monocytogenes Infection in Hairy Cell Leukemia: A Case Report and Literature Review

Cited by 4 publications

References 18 publications

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors

Listeria Monocytogenes, a Case of Mistaken Identity

Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group

Contact Info

Product

Resources

About